JP2020502262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502262A5 JP2020502262A5 JP2019547602A JP2019547602A JP2020502262A5 JP 2020502262 A5 JP2020502262 A5 JP 2020502262A5 JP 2019547602 A JP2019547602 A JP 2019547602A JP 2019547602 A JP2019547602 A JP 2019547602A JP 2020502262 A5 JP2020502262 A5 JP 2020502262A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- tumor cell
- seq
- cell line
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 210000004881 tumor cell Anatomy 0.000 claims 15
- 108010029697 CD40 Ligand Proteins 0.000 claims 10
- 230000002519 immonomodulatory effect Effects 0.000 claims 9
- 239000012528 membrane Substances 0.000 claims 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 8
- 102100032937 CD40 ligand Human genes 0.000 claims 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 7
- 229940030664 allogeneic tumor cell vaccine Drugs 0.000 claims 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 229940068196 placebo Drugs 0.000 claims 2
- 239000000902 placebo Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108700012920 TNF Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000005016 dendritic process Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023006527A JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425424P | 2016-11-22 | 2016-11-22 | |
| US62/425,424 | 2016-11-22 | ||
| PCT/US2017/063016 WO2018098279A1 (en) | 2016-11-22 | 2017-11-22 | Allogenic tumor cell vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006527A Division JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502262A JP2020502262A (ja) | 2020-01-23 |
| JP2020502262A5 true JP2020502262A5 (enExample) | 2021-01-14 |
| JP7629178B2 JP7629178B2 (ja) | 2025-02-13 |
Family
ID=62195656
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547602A Active JP7629178B2 (ja) | 2016-11-22 | 2017-11-22 | 同種異系腫瘍細胞ワクチン |
| JP2023006527A Pending JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006527A Pending JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11058752B2 (enExample) |
| EP (1) | EP3545001A4 (enExample) |
| JP (2) | JP7629178B2 (enExample) |
| KR (2) | KR20190100200A (enExample) |
| AU (1) | AU2017363256B2 (enExample) |
| WO (1) | WO2018098279A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201810871WA (en) | 2016-07-25 | 2019-01-30 | Us Health | Methods of producing modified natural killer cells and methods of use |
| US11185586B2 (en) | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
| EP3545001A4 (en) * | 2016-11-22 | 2020-10-21 | Alloplex Biotherapeutics | ALLOGENIC TUMOR CELL VACCINE |
| US10731128B2 (en) | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| CN112912389B (zh) | 2018-06-19 | 2024-04-19 | H·李·莫菲特癌症中心和研究所公司 | 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗 |
| BR112021009634A2 (pt) * | 2018-11-19 | 2021-08-10 | Board Of Regents, The University Of Texas System | gene suicida |
| AU2020264484A1 (en) | 2019-05-01 | 2021-11-04 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy |
| WO2020232408A1 (en) * | 2019-05-15 | 2020-11-19 | Genocea Biosciences, Inc. | Treatment methods |
| EP3976816A4 (en) * | 2019-05-28 | 2023-10-25 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR PRESERVING DNA METHYLATION |
| CN114222763A (zh) * | 2019-06-19 | 2022-03-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点 |
| AU2020371619A1 (en) * | 2019-10-22 | 2022-05-12 | Alloplex Biotherapeutics | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| JP2023504659A (ja) * | 2019-12-03 | 2023-02-06 | ニューボーゲン，インコーポレイティド | 腫瘍細胞ワクチン |
| EP4164750A4 (en) * | 2020-06-11 | 2024-04-17 | Alloplex Biotherapeutics | Allogeneic tumor cell vaccine |
| US20230257703A1 (en) * | 2020-06-19 | 2023-08-17 | Iowa State University Research Foundation, Inc. | Nanoscale polymeric micellar scaffolds for rapid and efficient antibody production |
| EP4526457A2 (en) * | 2022-06-30 | 2025-03-26 | Meridian Therapeutics, Inc. | A vaccine composition of cells expressing a lentiviral vector and methods of using |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882654A (en) * | 1989-11-03 | 1999-03-16 | Morton; Donald L. | Polyvalent melanoma vaccine |
| AU677165B2 (en) | 1991-10-04 | 1997-04-17 | Johns Hopkins University School Of Medicine, The | The regulation of systemic immune responses utilizing cytokines and antigens |
| WO1998006746A2 (en) | 1996-08-16 | 1998-02-19 | The Johns Hopkins University School Of Medicine | Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same |
| WO1999028349A2 (en) | 1997-12-02 | 1999-06-10 | Medarex, Inc. | CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS |
| WO2001009303A2 (en) * | 1999-07-30 | 2001-02-08 | Vical Inc. | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER |
| US20020006413A1 (en) | 2000-01-27 | 2002-01-17 | Sobol Robert E. | Genetically engineered tumor cell vaccines |
| AU2002366433A1 (en) | 2001-08-16 | 2003-09-09 | Human Genome Sciences, Inc. | Methods and compositions for treating metabolic bone diseases relating to human endokine alpha |
| WO2003045428A2 (de) | 2001-11-30 | 2003-06-05 | Medigene Aktiengesellschaft | Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung |
| WO2004098529A2 (en) * | 2003-04-30 | 2004-11-18 | Emory University | Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules |
| EP1667701A4 (en) | 2003-09-26 | 2007-02-14 | Univ Miami | TUMOR VACCINE |
| PT1699480E (pt) * | 2003-12-30 | 2011-08-30 | Mologen Ag | AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO |
| EP2032173A4 (en) * | 2006-06-06 | 2011-03-30 | Univ Rochester | HELPFREE-FREE HERPESVIRUS AMPLICON PARTICLES AND ITS USE |
| US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| WO2009095033A1 (en) * | 2008-01-31 | 2009-08-06 | Agirx Limited | Vaccine compositons |
| WO2011004201A1 (en) | 2009-07-10 | 2011-01-13 | Mark Lowdell | Preserved compositions of activated nk cells and methods of using the same |
| US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2016168197A1 (en) | 2015-04-15 | 2016-10-20 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
| WO2016198470A2 (en) | 2015-06-08 | 2016-12-15 | Lophius Biosciences Gmbh | Composition for determination of cell-mediated immune responsiveness |
| WO2017133175A1 (en) | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| EP3545001A4 (en) * | 2016-11-22 | 2020-10-21 | Alloplex Biotherapeutics | ALLOGENIC TUMOR CELL VACCINE |
| US11185586B2 (en) * | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
| US20200123566A1 (en) * | 2017-06-13 | 2020-04-23 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
| WO2020040327A1 (ko) * | 2018-08-23 | 2020-02-27 | 광주과학기술원 | 시클로피록스의 hbv 코어조립 저해 용도 |
| AU2019398202A1 (en) * | 2018-12-11 | 2021-08-05 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
| EP4164750A4 (en) * | 2020-06-11 | 2024-04-17 | Alloplex Biotherapeutics | Allogeneic tumor cell vaccine |
-
2017
- 2017-11-22 EP EP17873638.5A patent/EP3545001A4/en active Pending
- 2017-11-22 JP JP2019547602A patent/JP7629178B2/ja active Active
- 2017-11-22 KR KR1020197018010A patent/KR20190100200A/ko not_active Ceased
- 2017-11-22 AU AU2017363256A patent/AU2017363256B2/en active Active
- 2017-11-22 US US15/821,105 patent/US11058752B2/en active Active
- 2017-11-22 WO PCT/US2017/063016 patent/WO2018098279A1/en not_active Ceased
- 2017-11-22 KR KR1020247004557A patent/KR20240024328A/ko active Pending
-
2021
- 2021-04-16 US US17/233,124 patent/US12403186B2/en active Active
-
2023
- 2023-01-19 JP JP2023006527A patent/JP2023055758A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502262A5 (enExample) | ||
| US11732017B2 (en) | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use | |
| JP7122336B2 (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| CN104087592B (zh) | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 | |
| MX2022012409A (es) | Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores. | |
| Deauvieau et al. | Human natural killer cells promote cross‐presentation of tumor cell‐derived antigens by dendritic cells | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2004537252A5 (enExample) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2017530114A (ja) | フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物 | |
| CN101824400A (zh) | 一种放大增殖抗原特异性t细胞的方法 | |
| Zhang et al. | Generation of mouse pluripotent stem cell–derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells | |
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| Lauterbach et al. | Genetic adjuvantation of recombinant MVA with CD40L potentiates CD8 T cell mediated immunity | |
| Dorn et al. | Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope | |
| Ni et al. | Antitumor vaccination by Newcastle Disease Virus Hemagglutinin–Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity | |
| Berzofsky | A push–pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses | |
| CN102898528B (zh) | 钙网蛋白-可溶性程序性死亡受体1的融合蛋白及其制备方法和用途 | |
| CN110234657B (zh) | 用于激活cd40和sting通路的表达基因佐剂的病毒载体构建体 | |
| JPWO2020163634A5 (enExample) | ||
| Zong et al. | Identification of Co-inhibitory receptors PD-1 and TIM-3 on t cells from gastric cancer patients | |
| US10226518B2 (en) | Ubiquitinylated proteins | |
| CN104761636B (zh) | 一种HLA-A33限制性eEF2表位多肽及其应用 | |
| US20200362014A1 (en) | Applications of soluble protein baff in b cell in-vitro culture and proliferation |